CN113616781A - 一种含有头孢洛宁的奶牛干乳期乳房炎制剂及其制备方法 - Google Patents
一种含有头孢洛宁的奶牛干乳期乳房炎制剂及其制备方法 Download PDFInfo
- Publication number
- CN113616781A CN113616781A CN202110956558.7A CN202110956558A CN113616781A CN 113616781 A CN113616781 A CN 113616781A CN 202110956558 A CN202110956558 A CN 202110956558A CN 113616781 A CN113616781 A CN 113616781A
- Authority
- CN
- China
- Prior art keywords
- cefalonium
- mastitis
- dairy cows
- breast
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000283690 Bos taurus Species 0.000 title claims abstract description 89
- 238000002360 preparation method Methods 0.000 title claims abstract description 59
- 208000004396 mastitis Diseases 0.000 title claims abstract description 58
- 235000013365 dairy product Nutrition 0.000 title claims abstract description 57
- 229950005258 cefalonium Drugs 0.000 claims abstract description 53
- FMZXNVLFJHCSAF-DNVCBOLYSA-N (6R,7R)-3-[(4-carbamoyl-1-pyridin-1-iumyl)methyl]-8-oxo-7-[(1-oxo-2-thiophen-2-ylethyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CC=3SC=CC=3)[C@H]2SC1 FMZXNVLFJHCSAF-DNVCBOLYSA-N 0.000 claims abstract description 52
- 210000000481 breast Anatomy 0.000 claims abstract description 52
- 238000000227 grinding Methods 0.000 claims abstract description 40
- 102000012265 beta-defensin Human genes 0.000 claims abstract description 27
- 108050002883 beta-defensin Proteins 0.000 claims abstract description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 26
- 238000010438 heat treatment Methods 0.000 claims abstract description 25
- 238000002156 mixing Methods 0.000 claims abstract description 25
- 238000002347 injection Methods 0.000 claims abstract description 18
- 239000007924 injection Substances 0.000 claims abstract description 18
- 239000004200 microcrystalline wax Substances 0.000 claims abstract description 17
- 235000019808 microcrystalline wax Nutrition 0.000 claims abstract description 17
- -1 polyoxypropylene Polymers 0.000 claims abstract description 17
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000000084 colloidal system Substances 0.000 claims abstract description 16
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims abstract description 16
- 229940093471 ethyl oleate Drugs 0.000 claims abstract description 16
- 238000001816 cooling Methods 0.000 claims abstract description 14
- 229920001451 polypropylene glycol Polymers 0.000 claims abstract description 13
- 239000004094 surface-active agent Substances 0.000 claims abstract description 10
- 239000000375 suspending agent Substances 0.000 claims abstract description 9
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 7
- 239000008158 vegetable oil Substances 0.000 claims abstract description 7
- 239000003871 white petrolatum Substances 0.000 claims description 12
- 102000008070 Interferon-gamma Human genes 0.000 claims description 7
- 108010074328 Interferon-gamma Proteins 0.000 claims description 7
- 229940044627 gamma-interferon Drugs 0.000 claims description 7
- 101001002617 Bos taurus Interleukin-2 Proteins 0.000 claims description 4
- 230000005965 immune activity Effects 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 229940051841 polyoxyethylene ether Drugs 0.000 claims description 3
- 229920000056 polyoxyethylene ether Polymers 0.000 claims description 3
- 235000012424 soybean oil Nutrition 0.000 claims description 3
- 239000003549 soybean oil Substances 0.000 claims description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
- 239000004166 Lanolin Substances 0.000 claims description 2
- 240000007472 Leucaena leucocephala Species 0.000 claims description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 239000010495 camellia oil Substances 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 229940088592 immunologic factor Drugs 0.000 claims description 2
- 229940039717 lanolin Drugs 0.000 claims description 2
- 235000019388 lanolin Nutrition 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 235000019198 oils Nutrition 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 235000011803 sesame oil Nutrition 0.000 claims description 2
- 239000008159 sesame oil Substances 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 abstract description 9
- 229940036735 ceftaroline Drugs 0.000 abstract description 5
- ZCCUWMICIWSJIX-NQJJCJBVSA-N ceftaroline fosamil Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OCC)C=2N=C(NP(O)(O)=O)SN=2)CC=1SC(SC=1)=NC=1C1=CC=[N+](C)C=C1 ZCCUWMICIWSJIX-NQJJCJBVSA-N 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 235000013336 milk Nutrition 0.000 description 43
- 239000008267 milk Substances 0.000 description 43
- 210000004080 milk Anatomy 0.000 description 43
- 238000003756 stirring Methods 0.000 description 33
- 230000000694 effects Effects 0.000 description 27
- 239000000243 solution Substances 0.000 description 22
- 230000000844 anti-bacterial effect Effects 0.000 description 18
- 230000003115 biocidal effect Effects 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 229940127130 immunocytokine Drugs 0.000 description 13
- 229930182555 Penicillin Natural products 0.000 description 11
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 11
- 244000052616 bacterial pathogen Species 0.000 description 11
- 230000001276 controlling effect Effects 0.000 description 11
- 239000011259 mixed solution Substances 0.000 description 11
- 229940049954 penicillin Drugs 0.000 description 11
- 238000007789 sealing Methods 0.000 description 11
- 230000001954 sterilising effect Effects 0.000 description 11
- 238000004659 sterilization and disinfection Methods 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 9
- 238000001228 spectrum Methods 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000002421 cell wall Anatomy 0.000 description 6
- 230000007012 clinical effect Effects 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 244000000010 microbial pathogen Species 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 4
- 241000588748 Klebsiella Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000204031 Mycoplasma Species 0.000 description 4
- 241000607142 Salmonella Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000005075 mammary gland Anatomy 0.000 description 4
- 210000002445 nipple Anatomy 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000006651 lactation Effects 0.000 description 3
- 210000004216 mammary stem cell Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000304886 Bacilli Species 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 102000000541 Defensins Human genes 0.000 description 2
- 108010002069 Defensins Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000001815 biotherapy Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 206010006262 Breast inflammation Diseases 0.000 description 1
- DBXFAPJCZABTDR-KUEXGRMWSA-N Cephalomannine Natural products O=C(O[C@@H]1C(C)=C2[C@@H](OC(=O)C)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@@H](O)[C@H](NC(=O)/C(=C\C)/C)c1ccccc1 DBXFAPJCZABTDR-KUEXGRMWSA-N 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- DBXFAPJCZABTDR-WBYYIXQISA-N cephalomannine Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(/C)=C/C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 DBXFAPJCZABTDR-WBYYIXQISA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
Abstract
本发明为一种含有头孢洛宁的用于预防和治疗奶牛干乳期乳房炎的制剂,其主要有效成分为头孢洛宁、免疫细胞因子、β‑防御素;辅料为助悬剂微晶蜡;表面活性剂聚氧丙烯醚;溶剂为植物油。本发明公开的一种含有头孢洛宁的用于预防和治疗奶牛干乳期乳房炎制剂的制备方法如下:1)将所述油酸乙酯和所述微晶蜡混合后,加热熔化,得到混合体系;2)降温后向所述混合体系中加入所述表面活性剂、所述免疫活性因子、β‑防御素及头孢洛宁,胶体磨研磨均匀,即得所述含有头孢洛宁的乳房注入剂。
Description
技术领域
本发明属于兽药制剂领域,具体涉及一种含有头孢洛宁的奶牛干乳期乳房炎制剂及其制备方法。
背景技术
奶牛乳房炎是由于乳房的局部血液循环障碍导致免疫功能低下,无法完全抵御致病菌微生物的入侵和增殖而造成乳房组织及乳头发炎的一种常见疾病,在临床上将奶牛乳房炎分为隐性乳房炎(亚临床型乳房炎)和临床型乳房炎。临床型乳房炎的患病奶牛主要表现为:乳房出现红肿热痛,乳汁颜色发黄或发红,有凝块、絮片等异常变化,产奶量下降或无奶,触摸乳房有硬块,部分奶牛出现精神沉郁,体温升高,食欲下降的全身症状。该病是危害奶牛业发展的四大疾病之一。
奶牛乳房炎给奶牛业带来巨大的经济损失,据统计,患乳房炎的奶牛损失比例中,奶牛隐性乳房炎占80%,经治疗以后的患病奶牛很难恢复到之前的产奶水平,同时奶牛乳房炎导致奶制品质量下降,严重危害人类的健康。奶牛乳房炎主要由金黄色葡萄球菌、链球菌、大肠杆菌、沙门氏菌、支原体、克雷伯氏菌等致病菌引起。奶牛乳房炎的治疗原则要以改善奶牛全身状况,提高机体免疫力,消灭病原菌,减轻或消除炎症,控制预防感染为主。
头孢洛宁是头孢菌素类抗生素,通过抑制细菌细胞壁的合成达到杀菌效果,对青霉素酶与β-内酰胺酶稳定,对葡萄球菌、链球菌、大肠杆菌、化脓隐秘杆菌等病原菌均有较好的体外抑菌作用,但对沙门氏菌、支原体、克雷伯氏菌等奶牛乳房内感染常见致病菌效果不显著。
专利申请CN103230365 A(201310087067.9)公开了一种在干奶期用于预防奶牛隐性乳腺炎的缓释乳房灌注剂的制备方法,但是抗生素的大量应用,致使一些常见的致病菌产生耐药性,治疗效果下降;同时乳汁中有大量抗生素的残留,直接影响到奶制品的质量,危害人类健康。专利申请CN1105943541 A(201610485853.8)公开了一种用于治疗奶牛干乳期乳房炎的长效乳房注入剂及其制备方法,该专利为抗生素和中药的复方制剂,虽然能够减少抗生素使用量,提高机体免疫力,但中药质量参差不齐,有效性及其安全性仍需要大量临床验证。
专利申请CN1652695 A(02829362.2)公开了一种改善动物生长性能的方法,该专利通过抗生素和免疫细胞因子联合使用来促进动物的生长和抗炎,以此来达到改善动物生长性能的目的。然而乳腺内感染和免疫本身是一个非常复杂的过程,免疫细胞因子调节其免疫应答机制也比较复杂,其本身的作用还受到诸如剂量、其它免疫细胞因子协同或拮抗的影响,单纯和抗生素联用效果不稳定。目前免疫细胞因子在组织修复,调节免疫力方面研究较多,在抗菌方面对金黄色葡萄球的效果显著,对其它乳房内易感细菌,如链球菌、大肠杆菌、沙门氏菌、支原体、克雷伯氏菌等致病菌研究较少,单纯和抗生素联用抗菌谱窄,不适用于各种致病菌引起的乳房炎。并且该专利给药方式不能进行乳房局部给药,在有针对性的治疗奶牛乳房炎方面存在缺陷。
免疫活性因子主要是介导和调节免疫应答及炎症反应,促进造血功能,参与组织修复。细胞因子间可形成大分子网格,既能协同,又能抑制,通过形成的细胞因子网络发挥整体效应,调节免疫平衡。免疫活性因子对遭受到病原微生物破坏的乳腺细胞进行有效修复的同时,使奶牛产奶量得到恢复,弥补抗生素疗法对奶牛机体产生的副作用。
β-防御素(Defensins)是抗菌肽中的一个家族,其广泛分布动植物和昆虫体内,具有热稳定、水溶性好等优点。它主要作用于病原微生物的细胞膜,对细菌的整个生命周期(静止期和繁殖期)均有作用,病原微生物不易对其产生抗体,不产生耐药性,具有抗生素无可比拟的优势。头孢洛宁的抑菌作用机制是通过阻断大分子生物合成进而阻断细胞壁的合成,只对增殖期的细菌有抑制作用,对静止期的细菌无抑制作用;头孢洛宁和免疫活性因子联用主要在革兰氏阳性球菌、革兰氏阴性球菌、革兰氏阳性杆菌疗效显著,但在革兰氏阴性杆菌、沙门氏菌、支原体、克雷伯氏菌等奶牛乳房内感染常见致病菌效果不显著。并且免疫细胞因子调节其免疫应答机制也比较复杂,其本身的作用还受到诸如剂量、其它免疫细胞因子协同或拮抗的影响,单纯和头孢洛宁联用效果不稳定。β-防御素(Defensins)的破膜机制,能够治愈多种致病菌引起的奶牛乳房炎,疗效显著,抗菌谱广、能够作用于细菌整个生命周期,疗程短,无耐药性,弥补了头孢洛宁和免疫活性因子联合使用抗菌谱窄、只作用于细菌繁殖期、疗程长的缺点。
基于上述原因,本申请提出一种头孢洛宁-免疫活性因子-β-防御素联合使用的制剂及制备方法。
发明内容
本发明的目的在于克服现有技术的不足,提供一种含有头孢洛宁的奶牛干乳期乳房炎制剂的制备方法。该制剂将免疫活性因子、β-防御素与头孢洛宁联合用药,头孢洛宁的抑菌作用机制是通过阻断大分子生物合成进而阻断细胞壁的合成,只对增殖期的细菌有抑制作用,对静止期的细菌无抑制作用;β-防御素作用于病原微生物的细胞膜,对细菌的整个生命周期(静止期和繁殖期)均有作用,且病原微生物不易对其产生抗体,不产生耐药性,二者联用协同发挥作用,疗效显著,既拓宽了抗菌谱又缩短了治疗疗程,能够治疗各种致病菌引起的乳房炎;免疫活性因子对遭受到病原微生物破坏的乳腺细胞进行有的效修复,使奶牛产奶量得到恢复,弥补抗生素疗法对奶牛机体产生的副作用。本发明提高了临床效果,缩短了奶牛产奶量恢复期,降低了抗生素的使用量,拓宽了抗菌谱;本发明制剂药物粒径为纳米级,药物释放量及释放速度大大提高,以最大有效血药浓度与病灶直接接触,生物利用度大大提高,缩短了用药时间,继而无弃奶期。
为实现上述目的,本发明的技术方案为:
一种含有头孢洛宁的奶牛干乳期乳房炎的乳房注入剂,其组成成分及质量百分比为:头孢洛宁3-5%、免疫活性因子0.1-1%、β-防御素0.1-1%、助悬剂0.5-2%;表面活性剂0.2-0.5%,余量为植物油。
优选的,含有头孢洛宁的奶牛干乳期乳房炎的乳房注入剂,其组成成分及质量百分比为:头孢洛宁:4%、免疫因子0.2%、β-防御素0.3%、助悬剂1.5%;表面活性剂0.2%,余量为油酸乙酯。
所述的免疫活性因子重组牛γ-干扰素(rboIFN-2)、重组牛白介素2(rboIL-2)、重组牛巨噬细胞集落刺激因子(rboGM-CSF)。
所述的助悬剂选自微晶蜡、白凡士林中的一种或两种的组合;优选微晶蜡。
所述的表面活性剂选自聚氧丙烯醚、聚氧乙烯醚、环氧乙烷、聚氧烯醇、羊毛脂、阿拉伯胶中的一种或多种,优选聚氧丙烯醚。
所述的植物油选择茶油、麻油、油酸乙酯、白油、大豆油中的一种或多种,优选油酸乙酯。
一种含有头孢洛宁的奶牛干乳期乳房炎的乳房注入剂的制备方法,包括如下步骤:
(1)按照比例将植物油和助悬剂混合后,加热至熔化,得到均匀混合体系;
(2)降温至室温后,向步骤(1)所得的混合体系中加入所述表面活性剂、免疫活性因子、β-防御素及头孢洛宁得到胶体;
(3)胶体磨研磨,调节磨盘间隙至8-10微米之间,研磨时间15-20min,即得目标产物。
所述的含有头孢洛宁的奶牛干乳期乳房炎的乳房注入剂的应用,在预防和治疗奶牛干乳期乳房炎方面的应用;
本发明一种含有头孢洛宁的用于预防和治疗奶牛干乳期乳房炎制剂的使用方法:乳管注入:干乳期奶牛,每乳室一支。
本发明提供一种纳米级乳房注入剂的制备方法,该乳房注入剂药物粒径为纳米级,释放量及释放速度大大提高,以最大有效血药浓度与病灶直接接触,提高了生物利用度;本发明将生物疗法与抗生素联合用药,抗生素和β-防御素分别作用于细菌的细胞壁和细胞膜,二者协同发挥作用,疗效显著;β-防御素的破膜机制能够超广谱杀菌,弥补了头孢洛宁抗菌谱窄的缺点;免疫活性因子能够快速修复乳房,提高奶牛免疫力并快速恢复产奶量。本发明制剂药物吸收代谢快,疗程短,原辅料残留少,长期给药奶牛乳汁中仍无原辅料的残留,无弃奶期,抗菌谱广,临床疗效显著,具有极高的推广价值。
本发明的有益效果是:
(1)本发明将难溶于水的抗菌药物头孢洛宁、具有免疫调节作用的免疫细胞因子和β-防御素制备成可以直接进入乳房注入的制剂,不进入血液循环,在体内无残留,降低了对奶牛的损害,该制剂使用不易被动物机体吸收的油酸乙酯作为溶媒,在油酸乙酯中加入增稠剂白凡士林起到吸收阻滞剂和稳定剂的作用,使该制剂有长效缓释的作用,干奶期给药可以保证药效能维持到下次产奶前,且无需弃奶期,减少了奶牛场的损失。
(2)本发明将生物疗法与抗生素联合使用,头孢洛宁和β-防御素分别作用于细菌的细胞壁和细胞膜,二者具有协同、互补、增效的作用,疗效显著,缩短了治疗疗程,在提高临床效果的基础上,减少了抗生素的使用量。头孢洛宁作用于细菌的细胞壁,只作用于细菌繁殖期;β-防御素的破膜机制能够作用于细菌的整个生命周期,弥补了头孢洛宁抗菌谱窄、耐药性的缺点;免疫细胞因子对遭受到病原微生物破坏的乳腺细胞可以有效修复,快速恢复奶牛产奶量,提高奶牛的免疫力,降低奶牛患乳房炎的概率,减弱抗生素疗法对奶牛机体产生的副作用。
(3)本发明制剂长期稳定性好,解决了市售制剂长期放置含量下降、降解杂质异烟酰胺增加,注入乳房内有效成分难以释放,生物利用度低的问题。
具体实施方式
以下以具体实施例对本发明做进一步说明,但不对本发明构成任何限制。
实施例1
一种含有头孢洛宁的奶牛干乳期乳房炎制剂,每100g组分如下:
制备方法如下:
(1)将处方量的白凡士林加入到油酸乙酯中,控制加热温度60±5℃,加热至白凡士林完全熔化,搅拌混合均匀,将溶液温度降至室温;
(2)向上述混合体系中加入聚氧丙烯醚、γ-干扰素(rboIFN-2)、β-防御素及头孢洛宁,搅拌混合均匀;
(3)将步骤(2)所述混合液用胶体磨研磨,调节磨盘间隙至8-10微米之间,研磨时间15-20min,将所得溶液边搅拌边倒入西林瓶中封口,20Kgy辐照灭菌,即得纳米级头孢洛宁乳房注入剂。
实施例2
一种含有头孢洛宁的奶牛干乳期乳房炎制剂,每100g组分如下:
制备方法如下:
(1)将处方量的微晶蜡加入到油酸乙酯中,控制加热温度90±5℃,加热至微晶蜡完全熔化,搅拌混合均匀,将溶液温度降至室温;
(2)向上述混合体系中加入聚氧烯醇、重组牛白介素2(rboIL-2)、β-防御素及头孢洛宁,搅拌混合均匀;
(3)将步骤(2)所述混合液用胶体磨研磨,调节磨盘间隙至8-10微米之间,研磨时间15-20min,将所得溶液边搅拌边倒入西林瓶中封口,20Kgy辐照灭菌,即得纳米级头孢洛宁乳房注入剂。
实施例3
一种含有头孢洛宁的奶牛干乳期乳房炎制剂,每100g组分如下:
制备方法如下:
(1)将处方量的微晶蜡加入到油酸乙酯中,控制加热温度90±5℃,加热至微晶蜡完全熔化,搅拌混合均匀,将溶液温度降至室温;
(2)向上述混合体系中加入聚氧丙烯醚、重组牛白介素2(rboIL-2)、β-防御素及头孢洛宁,搅拌混合均匀;
(3)将步骤(2)所述混合溶液用胶体磨研磨,调节磨盘间隙至8-10微米之间,研磨时间15-20min,将所得溶液边搅拌边倒入西林瓶中封口,20Kgy辐照灭菌,即得纳米级头孢洛宁乳房注入剂。
实施例4
一种含有头孢洛宁的奶牛干乳期乳房炎制剂,每100g组分如下:
制备方法如下:
(1)将处方量的白凡士林加入到大豆油中,控制加热温度60±5℃,加热至白凡士林完全熔化,搅拌混合均匀,将溶液温度降至室温;
(2)向上述混合体系中加入聚氧乙烯醚、γ-干扰素(rboIFN-2)、β-防御素及头孢洛宁,搅拌混合均匀;
(3)将步骤(2)所述混合液用胶体磨研磨,调节磨盘间隙至8-10微米之间,研磨时间15-20min,将所得溶液边搅拌边倒入西林瓶中封口,20Kgy辐照灭菌,即得纳米级头孢洛宁乳房注入剂。
实施例5
一种含有头孢洛宁的奶牛干乳期乳房炎制剂,每100g组分如下:
制备方法如下:
(1)将处方量的微晶蜡加入到油酸乙酯中,控制加热温度90±5℃,加热至微晶蜡完全熔化,搅拌混合均匀,将溶液温度降至室温;
(2)向上述混合体系中加入聚氧丙烯醚、γ-干扰素(rboIFN-2)、β-防御素及头孢洛宁,搅拌混合均匀;
(3)将步骤(2)所述混合液用胶体磨研磨,调节磨盘间隙至8-10微米之间,研磨时间15-20min,将所得溶液边搅拌边倒入西林瓶中封口,20Kgy辐照灭菌,即得纳米级头孢洛宁乳房注入剂。
实施例6
一种含有头孢洛宁的奶牛干乳期乳房炎制剂,每100g组分如下:
制备方法如下:
(1)将处方量的白凡士林加入到油酸乙酯中,控制加热温度60±5℃,加热至白凡士林完全熔化,搅拌混合均匀,将溶液温度降至室温;
(2)向上述混合体系中加入聚氧丙烯醚、rboGM-CSF、β-防御素及头孢洛宁,搅拌混合均匀;
(3)将步骤(2)所述混合液用胶体磨研磨,调节磨盘间隙至8-10微米之间,研磨时间15-20min,将所得溶液边搅拌边倒入西林瓶中封口,20Kgy辐照灭菌,即得纳米级头孢洛宁乳房注入剂。
实施例7
一种含有头孢洛宁的奶牛干乳期乳房炎制剂,每100g组分如下:
(1)将处方量的微晶蜡加入到油酸乙酯中,控制加热温度90±5℃,加热至微晶蜡完全熔化,搅拌混合均匀,将溶液温度降至室温;
(2)向上述混合体系中加入聚氧丙烯醚、rboGM-CSF及头孢洛宁,搅拌混合均匀;
(3)将步骤(2)所述混合液用胶体磨研磨,调节磨盘间隙至8-10微米之间,研磨时间15-20min,将所得溶液边搅拌边倒入西林瓶中封口,20Kgy辐照灭菌,即得纳米级头孢洛宁乳房注入剂。
实施例8
一种含有头孢洛宁的奶牛干乳期乳房炎制剂,每100g组分如下:
(1)将处方量的微晶蜡加入到油酸乙酯中,控制加热温度90±5℃,加热至微晶蜡完全熔化,搅拌混合均匀,将溶液温度降至室温;
(2)向上述混合体系中加入聚氧丙烯醚、rboGM-CSF及头孢洛宁,搅拌混合均匀;
(3)将步骤(2)所述混合液用胶体磨研磨,调节磨盘间隙至8-10微米之间,研磨时间15-20min,将所得溶液边搅拌边倒入西林瓶中封口,20Kgy辐照灭菌,即得纳米级头孢洛宁乳房注入剂。
实施例9
一种含有头孢洛宁的奶牛干乳期乳房炎制剂,每100g组分如下:
(1)将处方量的微晶蜡加入到油酸乙酯中,控制加热温度90±5℃,加热至微晶蜡完全熔化,搅拌混合均匀,将溶液温度降至室温;
(2)向上述混合体系中加入聚氧丙烯醚、γ-干扰素(rboIFN-2)及头孢洛宁,搅拌混合均匀;
(3)将步骤(2)所述混合液用胶体磨研磨,调节磨盘间隙至8-10微米之间,研磨时间15-20min,将所得溶液边搅拌边倒入西林瓶中封口,20Kgy辐照灭菌,即得纳米级头孢洛宁乳房注入剂。
对比例1
一种含有头孢洛宁的奶牛干乳期乳房炎制剂,每100g组分如下:
制备方法如下:
(1)将处方量的白凡士林加入到油酸乙酯中,控制加热温度60±5℃,加热至白凡士林完全熔化,搅拌混合均匀,将溶液温度降至室温;
(2)向上述混合体系中加入聚氧丙烯醚、头孢洛宁、β-防御素,搅拌混合均匀;
(3)将步骤(2)所述混合液用胶体磨研磨,调节磨盘间隙至8-10微米之间,研磨时间15-20min,将所得溶液边搅拌边倒入西林瓶中封口,20Kgy辐照灭菌,即得β-防御素单方制剂。
对比例2
一种含有头孢洛宁的奶牛干乳期乳房炎制剂,每100g组分如下:
制备方法如下:
(1)将处方量的白凡士林加入到油酸乙酯中,控制加热温度60±5℃,加热至白凡士林完全熔化,搅拌混合均匀,将溶液温度降至室温;
(2)向上述混合体系中加入聚氧丙烯醚、头孢洛宁、γ-干扰素(rboIFN-2),搅拌混合均匀;
(3)将步骤(2)所述混合液用胶体磨研磨,调节磨盘间隙至8-10微米之间,研磨时间15-20min,将所得溶液边搅拌边倒入西林瓶中封口,20Kgy辐照灭菌,即得免疫活性因子单方制剂。
一、药物长期稳定性实验
表1长期(25℃,RH60%)试验条件下头孢洛宁、免疫细胞因子及β-防御素含量检测结果
本发明样品长期稳定实验条件下,头孢洛宁、免疫细胞因子、β-防御素含量无明显变化,本品2年内质量稳定可控。
二、临床实验研究
1、受试对象:延庆某奶牛场,经诊断确定为临床型乳房炎的奶牛100头。
2、试验药物:
1)本发明产品头孢洛宁复方乳房注入剂(干乳期)(实施例1)
2)某公司市售头孢洛宁乳房注入剂(干乳期),规格3g:250mg
3)对比例1(β-防御素单方制剂)
4)对比例2(免疫细胞因子单方制剂)
3、实验方法:
将诊断为乳房炎的奶牛随机分为实验组和对照组,实验组奶牛采用的治疗方法是取本发明实施例5的乳房注入剂,对照组奶牛采用的治疗方法是分别取某公司市售头孢洛宁乳房注入剂(干乳期)、对比例1(β-防御素单方制剂)、对比例2(免疫细胞因子单方制剂),在进入干乳期前的最后一次挤奶结束后,用消毒药液浸泡乳头约30秒,然后进行乳头内灌注给药,每个乳区一支,给药一次。灌注时将含药推注管头插入乳头,轻轻推压活塞,将药物缓缓注入乳池内,随后轻轻按摩相应乳区,使药物均匀分布。分别在干乳期前最后一次挤奶和产犊后第一次挤奶7d内,采集奶样进行细菌学检查和牛奶体细胞测定、抗生素残留检测。考察奶牛用药前后的乳房局部临床症状、泌乳能力与乳汁状况,考察奶牛产奶量的变化,综合评价本发明的疗效。具体考察结果见表2-6。
表2试验奶牛各时间点不同乳区所采奶样细菌分离情况
实验结果表明,含有一定比例的头孢洛宁和β-防御素、免疫细胞因子的复方制剂有较好的抑菌效果,其中实施5抑菌效果最为明显,在9个实施例中,实施1给药后细菌残留株数略多,但抑菌效果仍明显优于对比例1(β-防御素单方制剂)、对比例2(免疫细胞因子单方制剂)。基于以上实验数据,头孢洛宁和β-防御素、免疫细胞因子制备成复方制剂后,降低了三者的使用比例,并起到了增效的作用。
表3乳房炎检测法(CMT)判断方法及标准
表4奶牛乳房炎治疗效果判断标准
表5各试验组奶牛乳区用药前后奶牛中体细胞数结果统计
表6各试验组奶牛用药前后临床效果综合评价结果
各试验组奶牛乳区用药前后临床效果评价表明,本发明制备的一种头孢洛宁、免疫细胞因子、β-防御素复方乳房注入剂临床效果明显优于市售品及对比例,本品临床效果显著。
表7厂给药愈后奶牛中乳汁中抗生素残留检测(无弃奶期)
实验结果表明,本发明给药后奶牛乳汁中无抗生素残留,使用过程中无弃奶期,继而无需弃奶,增加了奶牛厂收入。
表8愈后奶牛日均产奶量统计
实验结果表明,由于免疫活性细胞对奶牛乳腺细胞具有修复作用,本发明给药后,奶牛产奶量较给药前有所提高,说明头孢洛宁+β-防御素+免疫细胞因子的复方制剂不但对奶牛乳腺炎效果明显,还能调节免疫系统,修复乳腺细胞受损组织,提高产奶量,继而提高农场的经济收入。
4、实验结论
临床试验结果表明,本发明所述的药物是一种预防及治疗奶牛干乳期乳房炎的长效的复方制剂,由体外抑菌试验及临床试验结果表明,复方头孢洛宁、β-防御素和免疫活性因子有较强的抑菌作用,联合使用具有协同、互补、增效的作用,缩短了治疗疗程,拓宽了抗菌谱,避免了高浓度抗生素在牛奶中的残留;该乳房注入剂可维持在奶牛整个干乳期内有效,并且无弃奶期,泌乳期无需弃奶,能有效治疗干奶期隐性乳房炎、预防干乳期间新的感染,显著降低下一个泌乳期乳房炎的发病率;该乳房注入剂中的免疫细胞因子可增强奶牛的免疫力,修复奶牛受损的乳腺细胞,提高奶牛的产奶量,有极高的经济价值;该制剂采用一次性预充式注射器,不易造成乳头污染及细菌交叉感染。本发明安全有效,使用方便、成本低廉,具有很好的临床推广性。
Claims (8)
1.一种含有头孢洛宁的奶牛干乳期乳房炎的乳房注入剂,其特征在于,其组成成分及质量百分比为:头孢洛宁3-5%、免疫活性因子0.1-1%、β-防御素0.1-1%、助悬剂0.5-2%;表面活性剂0.2-0.5%,余量为植物油。
2.如权利要求1所述的含有头孢洛宁的奶牛干乳期乳房炎的乳房注入剂,其特征在于,含有头孢洛宁的奶牛干乳期乳房炎的乳房注入剂,其组成成分及质量百分比为:头孢洛宁:4%、免疫因子0.2%、β-防御素0.3%、助悬剂1.5%;表面活性剂0.2%,余量为油酸乙酯。
3.含有头孢洛宁的奶牛干乳期乳房炎的乳房注入剂,其特征在于,所述的免疫活性因子重组牛γ-干扰素、重组牛白介素2、重组牛巨噬细胞集落刺激因子。
4.如权利要求1所述的含有头孢洛宁的奶牛干乳期乳房炎的乳房注入剂,其特征在于,所述的助悬剂选自微晶蜡、白凡士林中的一种或两种的组合。
5.如权利要求1所述的含有头孢洛宁的奶牛干乳期乳房炎的乳房注入剂,其特征在于,所述的表面活性剂选自聚氧丙烯醚、聚氧乙烯醚、环氧乙烷、聚氧烯醇、羊毛脂、阿拉伯胶中的一种或多种。
6.如权利要求1所述的含有头孢洛宁的奶牛干乳期乳房炎的乳房注入剂,其特征在于,所述的植物油选择茶油、麻油、油酸乙酯、白油、大豆油中的一种或多种。
7.一种含有头孢洛宁的奶牛干乳期乳房炎的乳房注入剂的制备方法,其特征在于,包括如下步骤:
(1)按照比例将植物油和助悬剂混合后,加热至熔化,得到均匀混合体系;
(2)降温至室温后,向步骤(1)所得的混合体系中加入所述表面活性剂、免疫活性因子、β-防御素及头孢洛宁得到胶体;
(3)胶体磨研磨,调节磨盘间隙至8-10微米之间,研磨时间15-20min,即得目标产物。
8.如权利要求1所述的含有头孢洛宁的奶牛干乳期乳房炎的乳房注入剂的应用,其特征在于,在预防和治疗奶牛干乳期乳房炎方面的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110956558.7A CN113616781B (zh) | 2021-08-19 | 2021-08-19 | 一种含有头孢洛宁的奶牛干乳期乳房炎制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110956558.7A CN113616781B (zh) | 2021-08-19 | 2021-08-19 | 一种含有头孢洛宁的奶牛干乳期乳房炎制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113616781A true CN113616781A (zh) | 2021-11-09 |
CN113616781B CN113616781B (zh) | 2024-01-09 |
Family
ID=78386751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110956558.7A Active CN113616781B (zh) | 2021-08-19 | 2021-08-19 | 一种含有头孢洛宁的奶牛干乳期乳房炎制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113616781B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114404365A (zh) * | 2022-01-18 | 2022-04-29 | 山东鲁抗舍里乐药业有限公司 | 头孢洛宁乳房注入剂及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5124145A (en) * | 1989-10-24 | 1992-06-23 | Ciba-Geigy Canada Ltd. | Method for the prevention and treatment of bovine mastitis |
CN102524558A (zh) * | 2010-12-27 | 2012-07-04 | 内蒙古伊利实业集团股份有限公司 | 一种治疗奶牛隐性乳房炎的饲料添加剂 |
CN105943541A (zh) * | 2016-06-27 | 2016-09-21 | 齐鲁动物保健品有限公司 | 用于治疗奶牛干乳期乳房炎的长效乳房注入剂及其制备方法 |
-
2021
- 2021-08-19 CN CN202110956558.7A patent/CN113616781B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5124145A (en) * | 1989-10-24 | 1992-06-23 | Ciba-Geigy Canada Ltd. | Method for the prevention and treatment of bovine mastitis |
CN102524558A (zh) * | 2010-12-27 | 2012-07-04 | 内蒙古伊利实业集团股份有限公司 | 一种治疗奶牛隐性乳房炎的饲料添加剂 |
CN105943541A (zh) * | 2016-06-27 | 2016-09-21 | 齐鲁动物保健品有限公司 | 用于治疗奶牛干乳期乳房炎的长效乳房注入剂及其制备方法 |
Non-Patent Citations (2)
Title |
---|
冯言言;陈玲;郑莉;林红;尹伶灵;孔梅;吴连勇;: "头孢洛宁乳房注入剂(干乳期)防治奶牛干乳期乳房炎的研究进展", 中国兽医杂志, no. 02 * |
薛梅;: "头孢洛宁乳房注入剂对奶牛干乳期乳房炎的防治效果", 江苏农业科学, no. 14 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114404365A (zh) * | 2022-01-18 | 2022-04-29 | 山东鲁抗舍里乐药业有限公司 | 头孢洛宁乳房注入剂及其制备方法和应用 |
CN114404365B (zh) * | 2022-01-18 | 2023-03-14 | 山东鲁抗舍里乐药业有限公司 | 头孢洛宁乳房注入剂及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113616781B (zh) | 2024-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103976947B (zh) | 一种含酶油悬浮剂及其制备方法与应用 | |
US8765819B2 (en) | Composition comprising benzoic acid in combination with organic acid preservatives as active ingredients and the use thereof | |
KR20100088389A (ko) | 봉독과 생약추출물을 유효성분으로 하는 천연항생제 및 이의 제조방법 | |
US20170290854A1 (en) | Compositions and methods for treating and preventing bacterial infections | |
CN113616781B (zh) | 一种含有头孢洛宁的奶牛干乳期乳房炎制剂及其制备方法 | |
CN104606218A (zh) | 一种治疗奶牛泌乳期乳房炎的乳房注入剂及其制备方法 | |
CN113082060B (zh) | 一种奶牛乳房炎治疗用噬菌体鸡尾酒制剂制备与应用 | |
CN113730486A (zh) | 一种用于治疗乳腺炎的中药膏剂的制备及应用方法 | |
CN103893108A (zh) | 一种干乳期硫酸头孢喹肟的乳房注入剂组方及其制备方法 | |
RU2706689C1 (ru) | Способ лечения мастита у коров | |
KR101156082B1 (ko) | 젖소 유방염 치료용 조성물 | |
CN105726461B (zh) | 一种盐酸头孢噻呋干乳期乳房注入剂 | |
CN109432092B (zh) | 一种泌乳期复方抗菌制剂及其制备方法与应用 | |
CN1520881A (zh) | 一种用于防治奶牛乳腺炎的杀菌制剂及其制备方法 | |
RU2598338C1 (ru) | Способ лечения серозного мастита крупного рогатого скота | |
CN109045044B (zh) | 一种复方药剂及其制备方法、用途 | |
CN105749260A (zh) | 一种盐酸溶菌酶阴道片及其制备方法和应用 | |
CN111494509A (zh) | 一种主治奶牛乳房炎的双丁中药提取注射液及其制备工艺 | |
KR20100089394A (ko) | 오배자 추출물을 유효성분으로 함유하는 젖소 유방염의 예방 및 치료용 조성물 | |
US20190314460A1 (en) | Ovotransferrin treatment for the reproductive tract | |
CN116270805B (zh) | 一种用于奶牛乳腺炎的药物组合物及其制备方法 | |
WO2021039951A1 (ja) | 乳房炎用注入剤 | |
CN104622803A (zh) | 一种治疗泌乳期奶牛乳房炎的乳房注入剂及制备方法 | |
KR20070059787A (ko) | 은 나노입자의 콜로이드 용액을 포함하는 동물의 유방염예방 또는 치료용 조성물 및 그를 이용하여 동물의유방염을 예방 또는 치료하는 방법 | |
CN1286463C (zh) | 一种用于防治奶牛乳房炎的干奶牛乳房灌注剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |